Sensus Healthcare (NASDAQ:SRTS) Downgraded by B. Riley to “Neutral”

B. Riley downgraded shares of Sensus Healthcare (NASDAQ:SRTS) from a buy rating to a neutral rating in a research report released on Thursday morning, Briefing.com Automated Import reports. They currently have $5.50 price objective on the stock, down from their prior price objective of $14.00.

SRTS has been the subject of several other reports. TheStreet upgraded Sensus Healthcare from a d+ rating to a c- rating in a research note on Monday, August 26th. ValuEngine lowered Sensus Healthcare from a buy rating to a hold rating in a research note on Thursday, October 17th. Maxim Group set a $11.00 price objective on Sensus Healthcare and gave the stock a buy rating in a research note on Friday, August 9th. Finally, HC Wainwright restated a buy rating and issued a $10.00 price objective on shares of Sensus Healthcare in a research note on Thursday. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and four have given a buy rating to the company’s stock. The company currently has an average rating of Hold and a consensus target price of $8.30.

Sensus Healthcare stock traded down $0.21 during trading hours on Thursday, hitting $3.80. 73,900 shares of the stock traded hands, compared to its average volume of 31,014. The company has a market cap of $93.54 million, a PE ratio of -27.14 and a beta of -0.41. Sensus Healthcare has a one year low of $3.71 and a one year high of $9.23. The firm’s 50-day moving average price is $5.73 and its two-hundred day moving average price is $5.72.

Sensus Healthcare (NASDAQ:SRTS) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.05) by $0.01. The firm had revenue of $5.84 million during the quarter, compared to analyst estimates of $7.77 million. Sensus Healthcare had a negative return on equity of 8.82% and a negative net margin of 8.65%. On average, equities research analysts predict that Sensus Healthcare will post -0.12 earnings per share for the current year.

A number of institutional investors have recently modified their holdings of the stock. Essex Investment Management Co. LLC bought a new position in Sensus Healthcare in the 3rd quarter worth $540,000. Susquehanna International Group LLP boosted its holdings in Sensus Healthcare by 69.9% in the 2nd quarter. Susquehanna International Group LLP now owns 27,492 shares of the company’s stock worth $152,000 after buying an additional 11,311 shares during the period. BlackRock Inc. boosted its holdings in Sensus Healthcare by 40.7% in the 2nd quarter. BlackRock Inc. now owns 103,643 shares of the company’s stock worth $574,000 after buying an additional 29,990 shares during the period. Heartland Advisors Inc. boosted its holdings in Sensus Healthcare by 150.0% in the 2nd quarter. Heartland Advisors Inc. now owns 375,000 shares of the company’s stock worth $2,078,000 after buying an additional 225,000 shares during the period. Finally, Wells Fargo & Company MN bought a new position in Sensus Healthcare in the 2nd quarter worth $30,000. 9.95% of the stock is owned by institutional investors.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc manufactures and markets superficial radiation therapy devices to healthcare providers worldwide. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates the embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.

Recommended Story: What does earnings per share mean?

Analyst Recommendations for Sensus Healthcare (NASDAQ:SRTS)

Receive News & Ratings for Sensus Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sensus Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.